Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs

Research output: Contribution to journalArticle

Authors

  • CL Morgan
  • S Jenkins-Jones
  • M Evans
  • CD Poole
  • CJ Currie

Colleges, School and Institutes

Abstract

Aim: This study aimed to describe the pattern of weight change in people with type 2 diabetes (T2DM) over time and when using alternative treatment regimens. Methods: Data were from routine clinical practice in the UK. The weight trend was determined for each year from 1995 to 2010 for both prevalent and incident cases. Baseline weight was compared to absolute (mean Delta) and relative weights (% Delta) at 6, 12 and 24 months. Results: Mean, standardized weight in prevalent cases increased from 83.4 to 92.1 kg for males and from 73.5 to 79.9 kg for females between 1995 and 2010 (p <0.0001). For incident cases, the respective figures were 86.7 to 93.6 kg for males and 76.0 to 80.7 kg for females (p <0.001). Between baseline and 6, 12 and 24 months, there were significant changes in weight for the majority of the treatment regimens selected for analysis. The largest weight increase at 12 months was for the patients who were prescribed a combination therapy with insulin and a thiazolidinedione, with a median increase of 4.1 kg (95% CI -0.60 to 8.0, p <0.001). The largest weight decrease at 12 months was for the patients who were prescribed a combination therapy of metformin and exenatide, with a median decrease of -7.0 kg (95% CI -12.0 to -2.0, p <0.001). Conclusions: There was a continual increase in body weight in people with T2DM over time, and considerable differences in the impact on weight using alternative treatment regimens. At the same time, glycaemic control remained relatively unchanged.

Details

Original languageEnglish
Pages (from-to)424-432
Number of pages9
JournalDiabetes, Obesity and Metabolism
Volume14
Issue number5
Publication statusPublished - 1 May 2012

Keywords

  • secular trends, weight change, obesity, antidiabetic drugs, type 2 diabetes